Novo Nordisk A/S (NEO:NVON)

Market Cap	313.69B
Revenue (ttm)	66.98B
Net Income (ttm)	23.85B
Shares Out	n/a
EPS (ttm)	5.36
PE Ratio	13.15
Forward PE	12.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	98,268
Average Volume	73,672
Open	5.38
Previous Close	5.42
Day's Range	5.37 - 5.58
52-Week Range	4.83 - 10.80
Beta	n/a
RSI	38.62
Earnings Date	Aug 6, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Cboe Canada
• Ticker Symbol: NVON

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK